-
-
-
-
-
-
-
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
-
-
-
-
-
-
-
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
-
-
-
-
-
-
-
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
-
-
-
-
-
-
-
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
-
-
-
-
-
-
-
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
-
-
-
-
-
-
-
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
-
-
-
-
-
-
-
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
-
1,160,147 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

